

Colorectal cancer risk following appendectomy: a pooled analysis of three large prospective cohort studies

Dear Editor,

Appendectomy is usually performed to treat acute appendicitis although it may also be conducted in the absence of appendicitis when patients suffer from chronic abdominal pain. Resection is also known to mitigate the risk of ulcerative colitis [1], a risk factor for colorectal cancer. The impact of appendectomy on colorectal cancer risk, particularly in the long term, is unclear. The procedure was initially hypothesized to increase colorectal cancer risk due to decreased immunocompetency. However, recent studies conducted on clinical databases have found little evidence of an association between prior appendectomy and colorectal cancer risk, other than a short-term increase in risk following the procedure in older individuals [2–5]. These studies had various limitations. Firstly, they relied on matched cohorts of appendectomy and non-appendectomy participants, which may have resulted in biases, for example from precautionary removal of the appendix following other abdominal complaints. Secondly, appendectomy data may have been inaccurate due to incomplete medical histories, particularly the omission of appendectomies performed at younger ages. Thirdly, some studies were able to crudely adjust for known colorectal cancer risk factors such as body size, alcohol intake, and smoking status, but not potential confounders such as colorectal cancer screening and family history. In this study, we aimed to address these limitations by conducting a pooled study of over 590,000 participants from three large European prospective studies, the UK Biobank, the European Investigation into Cancer and Nutrition (EPIC), and the French E3N cohort. The large number of incident colorectal cancer cases and high-quality clinical, lifestyle and other epidemiological data collected in these well-characterized cohorts allowed us to robustly examine the association between appendectomy and colorectal cancer overall and across tumor anatomical subsites.

Abbreviations: HR, hazard ratio; CI, confidence interval; EPIC, European Investigation into Cancer and Nutrition

The UK Biobank cohort contributed 472,321 participants, of whom 55,075 (11.7%) had previously undergone appendectomy (Supplementary Materials). A total of 28,929 participants were included from the EPIC study, and 6,262 (21.6%) had reported prior appendectomy. E3N contributed 90,567 participants, of whom 20,418 (22.5%) had reported an appendectomy (Supplementary Table S1). A total of 591,817 participants were therefore included in the pooled study. The median follow-up durations starting from year of reported appendectomy to the end of followup were 47 years (range, 0-76 years), 51 years (range, 0-87 years), and 50 years (range, 0-84 years), respectively, for the three cohorts and did not differ appreciably between colorectal cancer cases and non-cases.

In the UK Biobank, EPIC, and E3N cohorts, 3,171, 576, and 1,080 incident cases of colorectal cancer were recorded during median follow-up times of 7.1 years (range, 0.0-10.0 years), 15.2 years (range, 0.0-18.9 years) and 24.3 years (range, 0.0-25.8 years), respectively. Overall associations between prior appendectomy and colorectal cancer were similar in the three cohort studies, and multivariable adjustment for known colorectal cancer risk factors did not impact the associations (Supplementary Table S2). In the pooled analysis, appendectomy was not associated with lower overall colorectal cancer risk, despite a 9% reduction in risk [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.79-1.02 (Figure 1). Appendectomy was associated with lower colorectal cancer risk in women (pooled HR = 0.89, 95% CI = 0.77-1.00) but not in men (pooled HR = 0.97, 95% CI = 0.84-1.10), and no heterogeneity by sex was detected ($I^2 = 0, P = 0.35$). However, appendectomy was associated with a lower risk of colon cancer overall (pooled HR = 0.90, 95% CI = 0.81-0.99) and distal colon cancer (pooled HR = 0.77,95% CI = 0.65-0.90), but not with proximal colon cancer (pooled HR = 0.99, 95% CI = 0.84-1.14) or rectal cancer (pooled HR = 0.94, 95% CI = 0.74-1.14). Heterogeneity of association was detected for proximal versus distal colon tumors ($I^2 = 76.2\%$, P = 0.04), but not for colon versus rectal tumors ($I^2 = 0, P = 0.61$). These associations have not been published previously.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.

Cancer subsite and group)	HR (95% CI)
Colorectal All participants UK Biobank EPIC E3N I ² = 55.3%, P = 0.11 Women UK Biobank	* * *	0.95 (0.85-1.05) 1.01 (0.83-1.23) 0.80 (0.69-0.93) 0.91 (0.79-1.02) 0.92 (0.79-1.09)
EPIC E3N <i>I</i> ² = 38.4%, <i>P</i> = 0.2 Men	→	1.01 (0.81-1.26) 0.80 (0.69-0.93) 0.89 (0.77-1.00)
EPIC $I^2 = 0\%, P = 0.77$	*	0.97 (0.84-1.11) 1.04 (0.66-1.65) 0.97 (0.84-1.10)
All participants UK Biobank EPIC E3N $l^2 = 0\%, P = 0.62$ Women	* * *	0.93 (0.82-1.06) 0.93 (0.73-1.18) 0.83 (0.69-1.01) 0.90 (0.81-0.99)
UK Biobank EPIC E3N I ² =0%, P=0.71 Men	_+ + + ♦	0.90 (0.74-1.08) 0.95 (0.73-1.24) 0.83 (0.69-1.01) 0.88 (0.77-0.98)
UK Biobank EPIC $I^2 = 0\%, P = 0.66$		0.97 (0.81-1.16) 0.84 (0.46-1.55) 0.95 (0.79-1.12)
All participants UK Biobank EPIC E3N $l^2 = 14.3\%, P = 0.29$ Women	•••	1.03 (0.87-1.24) 1.17 (0.86-1.59) 0.86 (0.66-1.11) 0.99 (0.84-1.14)
UK Biobank EPIC E3N $l^2 = 16.1\%, P = 0.29$ Men	•••	1.03 (0.80-1.32) 1.21 (0.86-1.69) 0.86 (0.66-1.11) 0.98 (0.80-1.16)
UK Biobank EPIC I ² = 0%, <i>P</i> = 0.95		1.04 (0.81-1.34) 1.01 (0.44-2.29) 1.04 (0.78-1.29)
Distal colon All participants UK Biobank EPIC E3N $l^2 = 0\%, P = 0.61$ Women	- + - +	0.80 (0.65-0.99) 0.65 (0.43-0.98) 0.81 (0.62-1.07) 0.77 (0.65-0.90)
UK Biobank EPIC E3N <i>I</i> ² = 0%, <i>P</i> = 0.55		0.65 (0.46-0.91) 0.65 (0.41-1.03) 0.81 (0.62-1.07) 0.71 (0.57-0.86)
UK Biobank EPIC $I^2 = 0\%, P = 0.51$		0.94 (0.72-1.23) 0.68 (0.27-1.72) 0.91 (0.67-1.15)
Rectal All participants UK Biobank EPIC E3N I ² = 48.9%, P = 0.13	• • •	0.98 (0.81-1.17) 1.22 (0.87-1.72) 0.78 (0.59-1.02) 0.94 (0.74-1.14)
Women UK Biobank EPIC E3N I ² = 33.5%, P = 0.24		1.01 (0.74-1.36) 1.15 (0.78-1.71) 0.78 (0.59-1.02) 0.92 (0.70-1.14)
UK Biobank EPIC $I^2 = 0\%, P = 0.37$	→ →	0.96 (0.77-1.21) 1.48 (0.74-2.99) 0.98 (0.77-1.20)
	0 0.5 1 1.5 2 Hazard ratio	

FIGURE 1 Random-effects meta-analyses for associations between prior appendectomy and colorectal cancer risk by tumor subsite and sex. EPIC, European Prospective Investigation into Cancer and Nutrition. The I^2 statistic for heterogeneity across cohorts and the corresponding *P* values are given. Estimates shown are pooled HR and 95% CI derived from Cox proportional hazard models performed in each individual cohort by random-effects

Cancer Communica<u>tions</u>

487

Associations by age at appendectomy (< 20 or \ge 20 years) remained similarly unchanged after multivariable adjustments in individual cohorts (Supplementary Table S3). In pooled analyses, prior appendectomy tended to be associated with a lower risk of cancer at most colorectal subsites, although these generally did not meet the threshold for statistical significance (Supplementary Figure S1). Little evidence of association between appendectomy and overall colorectal cancer risk by age at the procedure was found, with no heterogeneity detected ($I^2 = 0$). Likewise, for proximal and distal colon cancer, associations with appendectomy did not differ significantly between the two age groups ($I^2 = 0$, P = 0.81 and $I^2 = 40.0\%$, P = 0.20 for the two subsites, respectively).

In a sensitivity analysis using data from the UK Biobank only, the exclusion of participants who had previously reported a diagnosis of ulcerative colitis did not substantially change the appendectomy and colorectal cancer association (Supplementary Table S4). Likewise, the exclusion of participants that had reported previous irritable bowel syndrome, endometriosis, gallstones or gastro-esophageal reflux disease yielded unchanged risk estimates. The exclusion of ulcerative colitis cases from E3N did not appreciably change colorectal cancerappendectomy associations, nor did the inclusion of all reported appendicitis cases as additional instances of appendectomy (Supplementary Table S5).

To our knowledge, this is currently the first study to observe a reliable inverse association between appendectomy and colon cancer risk. Earlier studies may have included individuals whose appendectomies were related to other intestinal diseases, resulting in a higher shortterm risk of colorectal cancer in these groups. In contrast, participants included in the present study were recruited

meta-analyses. HR > 1 represents an increased risk of cancer for participants with appendectomy. Harmonized multivariable models were adjusted for body mass index (kg/m², continuous), physical activity (metabolic equivalent of task [MET] hours/week, categorical), height (cm, continuous), smoking status (current/former/never/unknown), and highest educational level (none or primary school/secondary school/technical or professional qualification/further education). In the UK Biobank dataset, history of cancer in first-degree relatives was additionally included in models and, in the E3N dataset, the colorectal cancer screening period (before/after 2002). In the E3N dataset, BMI, physical activity, smoking status, and history of colorectal cancer in first-degree relatives were modeled as time-varying. In the UK Biobank dataset, models were stratified by age at recruitment, Townsend deprivation index quintiles, and assessment center region. In the EPIC dataset, models were stratified by age at recruitment and center, and stratification variables were not used for the E3N models.

from healthy populations, regardless of prior appendectomy. Appendectomy was thus recorded at all points in the life course prior to the studies' respective baselines, sometimes early in life. The present study, therefore, leverages a much longer median follow-up from appendectomy (approximately 50 years) than previous studies (< 10 years). This extended follow-up was needed to assess the long-term impact of appendectomy.

Speculations on the mechanisms underlying the observed inverse associations between appendectomy and colon cancer risk could be as follows. First, the appendix is a source of the follicle centers necessary for the development of gut-associated lymphoid tissue, whose absence may limit inflammation and mitigate damaging autoreactivity in the colon [6]. A second possibility is the modification of intestinal microbiota profile and function. The appendix has been described as a "safe house" for commensal bacteria that may be reintroduced into the colon in case of disease [7]. Appendix microbiota exists as biofilms that contact colon epithelial cells and may promote colorectal cancer progression along the predominant adenoma pathway [8]. It also remains to be established why appendectomy was associated with a reduction in overall and distal colon cancer risk but not with the risk of proximal colon or rectal cancer. There is a progressive increase in pH, microbial load, and concentration of microbial metabolites from the proximal colon to the rectum [9], and marked differences exist between distal and proximal tumors in terms of mutation rate and genomic instability [10]. Also, the absence of the appendix and consequent changes in biofilm formation may impact carcinogenesis differentially in the proximal and distal colon. The promotion of carcinogenesis by biofilms has been reported to be common in the proximal but not the distal colon [8].

In conclusion, appendectomy prior to baseline recruitment was robustly and consistently associated with a lower risk of colon cancer, overall and at the distal subsite. Experimental studies are now required to identify which specific physiological changes induced by appendectomy may be beneficial against the development of colon tumorigenesis.

DECLARATIONS

AUTHORS' CONTRIBUTIONS

N.Murphy and GS, conceptualization of the study; JAR, NM, FA, data analysis; JAR, writing of the manuscript; AF, MC, MCBR, SSMC, MJG, reviewing and editing of the manuscript, and advice on interpretation of results; N.Murphy and GS, study supervision.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The UK Biobank obtained approval from the North-West Multicenter Research Ethics Committee, the National Information Governance Board for Health and Social Care in England and Wales, and the Community Health Index Advisory Group in Scotland. Ethical approval for the EPIC study was obtained from the International Agency for Research on Cancer and the ethical review boards of the participating institutes. The cohort was granted ethical approval by the French National Commission for Computed Data and Individual Freedom (Commission Nationale de l'Informatique et des Libertés). All participants from each of the three cohorts provided written informed consent.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

The French E3N cohort is maintained with the support of the Mutuelle Générale de l'Education Nationale (MGEN), Gustave Roussy and the French League against Cancer (LNCC). E3N-E4N is also supported by the French National Research Agency (ANR) under the Investment for the future Program (PIA) (ANR-10-COHO-0006) and by the French Ministry of Higher Education, Research and Innovation (subsidy #2102 918823). This work has been supported within the context of the ALLERCOLO project funded by Fondation ARC.

CONFLICT OF INTEREST

The authors declare there are no conflicts of interest.

ACKNOWLEDGMENTS

This work was conducted using the UK Biobank Resource under Application Number 25897 and we hereby acknowledge the participants and those involved in building the resource. We also express our gratitude to the Norfolk and Utrecht EPIC centers for the provision of participant data. We thank all women participating in the E3N cohort study run by The French National Institute for Health and Medical Research (Inserm) and acknowledge the continuing support of the MGEN, the Institut Gustave Roussy and the French League Against Cancer (Ligue Contre le Cancer). The work reported in this paper was performed during

CANCER

489

Agnès Fournier's term as a Visiting Scientist at the International Agency for Research on Cancer.

DATA AVAILABILITY STATEMENT

All participant data from this study are available to other researchers. Bonafide researchers can apply to use the UK Biobank dataset by registering and applying at http://ukbiobank.ac.uk/register-apply/. Data from the EPIC and E3N cohorts are available from the authors upon reasonable request, subject to appropriate data sharing agreements. Analysis code and protocols for this study are stored in a centralized online repository and access can be granted by the authors upon request.

Joseph A. Rothwell^{1,#} ⁽¹⁾ Nagisa Mori^{2,#} ⁽¹⁾ Fanny Artaud¹ Agnès Fournier¹ Marco Conte¹ Marie-Christine Boutron-Ruault¹ Simon S. M. Chan^{3,4} Marc J. Gunter² Neil Murphy^{2,#} Gianluca Severi^{1,5,#}

¹ Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Exposome and Heredity team, Centre for Epidemiology and Population Health (CESP U1018), Villejuif 94800, France ² Nutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), 150 Cours Albert Thomas, Lyon 69008, France

³ Department of Gastroenterology, Norfolk and Norwich University Hospital NHS Trust, Norwich NR4 7UY, United Kingdom

 ⁴ Department of Medicine, Bob Champion Research and Education Building, Norwich Medical School, University of East Anglia, Norwich NR4 7UQ, United Kingdom
⁵ Department of Statistics, Computer Science, Applications "G. Parenti", University of Florence, Florence 50134, Italy

Correspondence

Gianluca Severi, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Exposome and Heredity team, Centre for Epidemiology and Population Health (CESP U1018), 94800, Villejuif, France. Email: gianluca.severi@inserm.fr

Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer / World

Health Organization. [#]These authors contributed equally towards first or senior authorship.

ORCID

Joseph A. Rothwell https://orcid.org/0000-0002-6927-3360

Nagisa Mori D https://orcid.org/0000-0003-1721-4083

REFERENCES

- Radford-Smith GL, Edwards JE, Purdie DM, Pandeya N, Watson M, Martin NG, et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut. 2002;51(6):808-13.
- 2. Wu SC, Chen WTL, Muo CH, Ke TW, Fang CW, Sung FC. Association between Appendectomy and Subsequent Colorectal Cancer Development: An Asian Population Study. PLoS One. 2015;10(2).
- Song H, Abnet CC, Andren-Sandberg A, Chaturvedi AK, Ye WM. Risk of Gastrointestinal Cancers among Patients with Appendectomy: A Large-Scale Swedish Register-Based Cohort Study during 1970-2009. PLoS One. 2016;11(3).
- 4. Lee J, Choe S, Park JW, Jeong SY, Shin A. The Risk of Colorectal Cancer After Cholecystectomy or Appendectomy: A Populationbased Cohort Study in Korea. J Prev Med Public Health Yebang Uihakhoe Chi. 2018;51(6):281-8.
- 5. Park YY, Lee K-Y, Oh ST, Park SH, Han KD, Lee J. A link between appendectomy and gastrointestinal cancers: a large-scale population-based cohort study in Korea. Sci Rep. 2020;10(1):15670-.
- 6. Kooij IA, Sahami S, Meijer SL, Buskens CJ, te Velde AA. The immunology of the vermiform appendix: a review of the literature. Clin Exp Immunol. 2016;186(1):1-9.
- Bollinger RR, Barbas AS, Bush EL, Lin SS, Parker W. Biofilms in the large bowel suggest an apparent function of the human vermiform appendix. J Theor Biol. 2007;249(4):826-31.
- Dejea CM, Wick EC, Hechenbleikner EM, White JR, Welch JLM, Rossetti BJ, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Nat Acad Sci USA. 2014;111(51):18321-6.
- 9. Drewes JL, Housseau F, Sears CL. Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy. Br J Cancer. 2016;115(3):273-80.
- Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995-2001.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.